Arovella TherapeuticsASX:ALA EV-to-FCF is -8.72 as of Jun. 28, 2026. The stock has 1 warning sign investors should review. Among 336 Biotechnology companies, Arovella Therapeutics ranks worse than 297618.75% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Arovella Therapeutics's Enterprise Value is A$60.41 Mil.
Arovella Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-6.93 Mil. Therefore, Arovella Therapeutics's EV-to-FCF for today is -8.72.
The historical rank and industry rank for Arovella Therapeutics's EV-to-FCF or its related term are showing as below:
ASX:ALA'
s EV-to-FCF Range Over the Past 10 Years
Min: -21.98 Med: -4.49 Max: 0.13
Current: -8.72
During the past 13 years, the highest EV-to-FCF of Arovella Therapeutics was 0.13. The lowest was -21.98. And the median was -4.49.
ASX:ALA's EV-to-FCF is ranked worse than 100% of 336
companies
in the Biotechnology industry
Industry Median: 14.7
vs ASX:ALA: -8.72
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Arovella Therapeutics's PE Ratio (TTM) for today is calculated as:
Arovella Therapeutics's share price for today is A$0.066.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arovella Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.007.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arovella Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arovella Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arovella Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Arovella Therapeutics's EV-to-FCF falls into.
Arovella Therapeutics's current Enterprise Value is A$60.41 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arovella Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-6.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arovella Therapeutics (ASX:ALA) has a EV-to-FCF of -8.72 as of Jun. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Arovella Therapeutics and its competitors. According to the industry distribution chart, Arovella Therapeutics ranks #999999 out of 336 companies in the Biotechnology industry.
Is Arovella Therapeutics' EV-to-FCF too high?
Arovella Therapeutics' current EV-to-FCF is -8.72. Based on the distribution chart, Arovella Therapeutics ranks #999999 out of 336 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Arovella Therapeutics' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arovella Therapeutics ranks #999999 out of 336 companies for EV-to-FCF. This places Arovella Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 14.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.70, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Arovella Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arovella Therapeutics's current EV-to-FCF is -8.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arovella Therapeutics stock overvalued right now?
Arovella Therapeutics (ASX:ALA) has a current EV-to-FCF of -8.72. The current EV-to-FCF is -8.72. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Arovella Therapeutics (ASX:ALA), the current EV-to-FCF is -8.72 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ALA has been successfully added to your 